High Profile Clinical Trials 2023
Today's High-Profile Clinical Trials
Clinical trials are constantly testing the boundaries of scientific
breakthroughs, and it is always exciting to see the next stage of
advancement. Collected below are three ongoing and upcoming clinical
trials, along with an explanation of how they could change healthcare.
A New Alzheimer's Drug
Alzheimer's is one disease that has been stumping scientists for decades as
they attempt to better understand what triggers the disease and what fuels
its progression.
Currently, there is no cure for Alzheimer's, only treatments that slow
disease progression. However, an upcoming clinical trial is investigating
CT1812, a potential therapy to prevent and treat amyloid beta (Aß)
oligomer-induced membrane trafficking deficits, which have been linked with
early-onset Alzheimer's disease.
An upcoming clinical trial evaluating the
safety and efficacy of CT1812
in individuals with Mild to Moderate Alzheimer's Disease and will use the
drug CT1812 or placebo in its phase 2 trial, which will last approximately
6 months and will recruit 144 participants. Participants will be given
either 100 mg or 300 mg of CT1812 or a placebo, administered once a day
through oral applications.
CT1812 targets Aß oligomers through a novel mechanism and is the first
selective sigma-2 receptor antagonist to reach clinical trials. Past trials
have shown its ability to displace Aß oligomers bound to neuronal
receptors, which can modify Alzheimer's disease mechanisms. The researchers
hope to see that administration of CT1812 may prevent further
neurodegeneration in Alzheimer's disease patients.
View other clinical trials that are recruiting participants:
Alzheimer's Clinical Trials.
A Treatment for Triple Negative Breast Cancer
Many clinical trials surrounding breast cancer are currently ongoing,
including new treatment options, improved screening methods, and better
ways to raise awareness for one of the most common cancers in women.
One clinical trial shows promise in
addressing triple negative breast cancer
, which is challenging to treat since it does not express some of the
receptors frequently found on breast cancer cells (i.e., estrogen,
progesterone, HER2). This makes treatment much more difficult, as there are
fewer things for treatment to target.
A phase 2 clinical trial is currently evaluating the safety and
effectiveness of a combination treatment for metastatic triple negative
breast cancer utilizing niraparib, dostarlimab, and radiation therapy.
Niraparib is a PARP inhibitor, blocking DNA repair and preventing cancer
cells from repairing their damaged genetic code. While it has not yet been
approved for metastatic triple-negative breast cancer, it has been approved
for other uses. Dosterlimab is involved in immunotherapy and inhibits a
protein called PD-1, which is responsible for shutting down immune
responses that recognize and destroy cancer cells. It has not yet been FDA
approved for any disease.
Participants in this trial will receive the drugs for 2 years, although
they will stop the drugs if their triple-negative breast cancer worsens.
All participants will then receive follow-ups for 5 years. It is estimated
that 32 participants will be included in the study. The researchers hope
that this treatment combination will result in improved anti-cancer immune
responses and better tumor control.
View other clinical trials that are recruiting participants:
Breast Cancer Clinical Trials
.
Alternative Treatments for Depression
Other upcoming clinical trials are not investigating medication
effectiveness but the ability of a new treatment modality to treat a health
condition.
A clinical trial for individuals diagnosed with
major depressive disorder (MDD)
is testing a treatment using non-invasive transcranial direct current
stimulation (tDCS), which is increasing in use as a treatment for
depressive disorders.
The clinical trial is recruiting 100 patients per group, and they will
undergo treatment with tDCS or sham tDCS for 20-minute sessions spread over
the course of 12 days. The study aims to determine the feasibility and
effectiveness of the treatment by measuring regional cerebral blood flow
and administering a series of neurological tests. Researchers hope this
will offer a new treatment option for patients with MDD.
View other clinical trials that are recruiting participants:
Depression Clinical Trials
.
The Exciting Promise of Clinical Trials
From curing a disease to offering at-home treatment options, clinical
trials push the limits of healthcare, always with an end goal of improving
patient health. Additionally, clinical trials offer the chance to try new
treatments for broad or specific populations, allowing you to benefit from
the advancements of medicine first-hand.
To find clinical trials near you click the button below to begin your
search: